Dr Reddy's Pioneers Generic Semaglutide Launch in Canada

Dr Reddy's Laboratories has introduced its generic Semaglutide injection for type 2 diabetes treatment in Canada. The launch makes Canada the first G7 country authorizing this generic, following Health Canada's approval. Dr Reddy's aims to enhance patient access to affordable GLP-1 therapies globally.

Dr Reddy's Laboratories has announced the launch of its generic Semaglutide injection in Canada, targeting type 2 diabetes treatment. This move positions Canada as the first G7 nation to provide market authorization for this generic drug, following compliance approval from Health Canada earlier this year.

CEO Erez Israeli highlighted the company's preparedness to meet Canadian patient needs, driven by their extensive experience in complex drug formulations. He emphasized Dr Reddy's commitment to delivering cost-effective GLP-1 therapies.

The rollout in Canada follows a similar recent launch in India. Aimed at improving glycemic control in adults, the injection is available in pre-filled pens and will aid in expanding the company's global presence in diabetes care.